1.Sales and profit
See section β- Pulsenmore Ltd. had $11.6M of revenue in fiscal 2025, up 344.1% on the year before.
- Pulsenmore Ltd. lost $4.6M in fiscal 2025. From fiscal 2023 to 2025, diluted EPS grew β46.3% a year.
Pulsenmore Ltd.
PLSM Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2023βFY2025
Pulsenmore Ltd. had $11.6M of revenue in fiscal 2025, up 344.1% on the year before.
- Today
- 2.3%
- Previous close
- $1.77
- Market cap
- $11.1M
- P/E
- 2.4x
- 52-week range
-
$1.73 $7.36
Last close Β· Oct 26, 2026
$1.73
β$5.63 (β76.49%) since Jan 21, 2026
KIRAβs summary AI analyst
Hi! I read Pulsenmore Ltd.βs latest annual report (fiscal 2025). Here is what stands out:
1 strength 3 to watch
2.Cash and shareholders
See section β- Free cash flow was β$9.6M in fiscal 2025, β82.5% of revenue.
- No open-market insider trades in the last 12 months.
3.Financial health
See section β- Pulsenmore Ltd. passes 3 of 8 financial health tests (Piotroski F-score).
Pulsenmore Ltd. in 30 seconds
Good So-so Weak
Good
Are sales growing?
+344.1%
Yes. Sales grew 344.1% last year.
Weak
Does it make a profit?
β39.6%
No. It lost money last year.
Weak
Does profit turn into cash?
β82.5%
No. It spent more cash than it brought in.
Weak
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
For information
How is the share priced?
2.4x
One share costs 2.4 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$11.1M
Oct 26 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
2.4x
On $0.71 EPS (TTM)
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
KIRA summarises the numbers
-
Pulsenmore Ltd. had $11.6M of revenue in fiscal 2025, up 344.1% on the year before.
Revenue
FY23
Revenue $1.7M
FY24
Revenue $2.6M
FY25
Revenue $11.6M
Margins, % of revenue
FY23
Gross 35.6%
Operating β
Net β946.5%
FCF β866.1%
FY24
Gross 37.0%
Operating β
Net β380.3%
FCF β434.4%
FY25
Gross 84.2%
Operating β
Net β39.6%
FCF β82.5%
Gross
Operating
Net
FCF
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Pulsenmore Ltd. lost $4.6M in fiscal 2025.
From fiscal 2023 to 2025, diluted EPS grew β46.3% a year.
Net income
FY23
Net income β$15.9M
FY24
Net income β$9.9M
FY25
Net income β$4.6M
Diluted EPS
FY23
Diluted EPS $2.47
FY24
Diluted EPS $1.56
FY25
Diluted EPS $0.71
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
KIRA summarises the numbers
-
Free cash flow was β$9.6M in fiscal 2025, β82.5% of revenue.
Free cash flow
FY23
Free cash flow β$14.5M
FY24
Free cash flow β$11.3M
FY25
Free cash flow β$9.6M
Cash from operations vs capital spending
FY23
Cash from operations β$13.5M
Capital spending $1.1M
FY24
Cash from operations β$11.2M
Capital spending $0.1M
FY25
Cash from operations β$9.5M
Capital spending $0.0M
Cash from operations
Capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends, buybacks and share count
Dividends and buybacks
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY23
Diluted shares 0.01B
FY24
Diluted shares 0.01B
FY25
Diluted shares 0.01B
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
No open-market insider trades in the last 12 months.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Pulsenmore Ltd. can carry it.
Cash vs debt (incl. leases)
FY23
Cash $6.6M
Debt β
FY24
Cash $11.3M
Debt β
FY25
Cash $6.8M
Debt β
Cash
Debt
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $6.6M | $11.3M | $6.8M |
| Current ratio | β | 9.3x | 7.9x |
| Quick ratio | β | 7.7x | 6.0x |
| Total assets | β | $38.9M | $31.9M |
| Total liabilities | β | $12.3M | $5.9M |
| Shareholders' equity | $36.5M | $26.6M | $26.1M |
| Net debt (β = net cash) | β | β | β |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
FY23
Return on capital β
Return on equity β43.5%
Return on assets β
FY24
Return on capital β
Return on equity β31.5%
Return on assets β25.5%
FY25
Return on capital β
Return on equity β17.5%
Return on assets β13.0%
Return on capital
Return on equity
Return on assets
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
KIRA summarises the numbers
-
Pulsenmore Ltd. passes 3 of 8 financial health tests (Piotroski F-score).
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 3 | β / 5 | 3 / 8 |
| Accruals ratio | β | 3.3% | 13.9% |
| Altman Z'' | β | β | β |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
Every number, year by year.
3 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $1.7M | $2.6M | $11.6M |
| Gross profit | $0.6M | $1.0M | $9.8M |
| Research and development | $8.5M | $5.4M | $5.0M |
| Interest expense | $4.4M | $0.1M | $2.1M |
| Pretax income | β$15.8M | β$9.9M | β$4.6M |
| Income tax | $0.0M | β$0.0M | $0.0M |
| Net income | β$15.9M | β$9.9M | β$4.6M |
| Diluted EPS | $2.47 | $1.56 | $0.71 |
| Diluted shares | 0.01B | 0.01B | 0.01B |
| Cash flow | |||
| Cash from operations | β$13.5M | β$11.2M | β$9.5M |
| Capital expenditure | $1.1M | $0.1M | $0.0M |
| Free cash flow | β$14.5M | β$11.3M | β$9.6M |
| Depreciation and amortization | $0.7M | $0.8M | $0.8M |
| Stock-based compensation | $0.9M | $0.4M | $0.2M |
| Balance sheet | |||
| Cash and short-term investments | $6.6M | $11.3M | $6.8M |
| Current assets | β | $36.3M | $25.5M |
| Current liabilities | β | $3.9M | $3.2M |
| Inventory | β | $6.3M | $6.2M |
| Property and equipment, net | $2.5M | $2.1M | $1.8M |
| Total assets | β | $38.9M | $31.9M |
| Total liabilities | β | $12.3M | $5.9M |
| Shareholders' equity | $36.5M | $26.6M | $26.1M |
| Margins | |||
| Gross margin | 35.6% | 37.0% | 84.2% |
| Net margin | β946.5% | β380.3% | β39.6% |
| FCF margin | β866.1% | β434.4% | β82.5% |
| Returns | |||
| Return on equity | β43.5% | β31.5% | β17.5% |
| Return on assets | β | β25.5% | β13.0% |
| Return on tangible equity | β43.5% | β37.4% | β17.6% |
| Growth | |||
| Revenue growth | β | 55.6% | 344.1% |
| EPS growth | β | β37.0% | β54.2% |
| Share count change | β | 0.0% | 0.6% |
| Financial health | |||
| Current ratio | β | 9.3x | 7.9x |
| Quick ratio | β | 7.7x | 6.0x |
| Capital allocation | |||
| Capex / revenue | 63.5% | 5.3% | 0.3% |
| Stock comp / revenue | 53.0% | 14.4% | 1.7% |
| Quality scores | |||
| Piotroski F-score | β | β | 3.0 |
| Accruals ratio | β | 3.3% | 13.9% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0002064764). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in ILS under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only β not investment advice. Check the original filings before relying on any figure.